心力衰竭患者高强度小肌肉量训练:随机对照试验的推理和设计
Menaka Louis1,2, Rita Hwang2,3, Surendran Sabapathy2
1Chronic Disease and Post-Acute Programs, Gold Coast Hospital and Health Service, Robina Health Precinct, Robina, Queensland, Australia.
Physical therapy
|September 27, 2023
概括
这项研究调查了心力衰竭患者的高强度小肌肉量训练 (HISMT). 在心脏康复中集成的HISMT可以改善运动能力和肌肉功能,优化康复策略.
科学领域:
- 心脏病学 心脏病学
- 运动生理学 运动生理学
- 康复医学 康复医学 康复医学
背景情况:
- 心力衰竭与骨肌肉损伤有关,特别是在四头四腿肌.
- 小肌肉量训练在改善心力衰竭患者的这些障碍方面表现有前途.
- 在标准的临床康复环境中,这种培训的有效性需要进一步评估.
研究的目的:
- 确定将膝盖伸缩器的高强度小肌肉量训练 (HISMT) 整合到标准心力衰竭康复中的效果.
- 评估HISMT是否可以在临床背景下提高心力衰竭患者的运动能力,身体表现,肌肉力量和生活质量.
主要方法:
- 一个单盲,随机对照试验,涉及70名心力衰竭参与者.
- 参与者被随机分配到标准训练或HISMT加上12周的修改标准训练,每周两次.
- 主要结局是运动能力 (6分钟步行测试);次要结局包括身体表现,肌肉力量和生活质量.
主要成果:
- 该部分是在研究完成后填写的.
结论:
- 这项研究解决了了解小肌肉训练在常规心力衰竭临床条件下有效性的差距.
- 这些发现将有助于优化心力衰竭患者接受康复的运动处方.
相关概念视频
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure VII: Nursing Interventions
89
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
89
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Heart Failure I: Introduction
14
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
14
Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611


